{"denoms":[{"counts":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"402"},{"groupId":"BG003","value":"403"},{"groupId":"BG004","value":"115"},{"groupId":"BG005","value":"115"},{"groupId":"BG006","value":"1054"}],"units":"Participants"}],"groups":[{"description":"Participants initially received a starting dose of talazoparib 1 mg once daily (QD) in combination with enzalutamide 160 mg QD up until Day 66, then the dose of talazoparib was reduced to 0.5 mg QD based on results from a review of available safety and pharmacokinetic (PK) data (up to a maximum of 231.14 weeks for both talazoparib and enzalutamide as of 16 Aug 2022).","id":"BG000","title":"Part 1: Talazoparib 1 mg QD+Enzalutamide"},{"description":"Participants received talazoparib 0.5 mg QD in combination with enzalutamide 160 mg QD (up to a maximum of 180 weeks for talazoparib and 219.29 weeks for enzalutamide as of 16 Aug 2022).","id":"BG001","title":"Part 1: Talazoparib 0.5 mg QD+Enzalutamide"},{"description":"Participants were randomized to receive talazoparib 0.5 mg QD in combination with enzalutamide 160 mg QD (up to a maximum of 186.14 weeks for both talazoparib and enzalutamide as of 16 Aug 2022).","id":"BG002","title":"Part 2 Cohort 1: Talazoparib+Enzalutamide (All-comer)"},{"description":"Participants were randomized to receive placebo QD in combination with enzalutamide 160 mg QD (up to a maximum of 182 weeks for both placebo and enzalutamide as of 16 Aug 2022).","id":"BG003","title":"Part 2 Cohort 1: Placebo+Enzalutamide (All-comer)"},{"description":"Participants with DDR deficiencies were randomized to receive talazoparib 0.5 mg QD in combination with enzalutamide 160 mg QD (up to a maximum of 169.86 weeks for both talazoparib and enzalutamide as of 03 Oct 2022).","id":"BG004","title":"Part 2 Cohort 2: Talazoparib+Enzalutamide (DDR-deficient)"},{"description":"Participants with DDR deficiencies were randomized to receive placebo QD in combination with enzalutamide 160 mg QD (up to a maximum of 157 weeks for both placebo and enzalutamide as of 03 Oct 2022).","id":"BG005","title":"Part 2 Cohort 2: Placebo+Enzalutamide (DDR-deficient)"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"79"},{"groupId":"BG003","value":"94"},{"groupId":"BG004","value":"25"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"227"}],"title":"<65 years"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"188"},{"groupId":"BG003","value":"175"},{"groupId":"BG004","value":"53"},{"groupId":"BG005","value":"55"},{"groupId":"BG006","value":"483"}],"title":"65-<75 years"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"135"},{"groupId":"BG003","value":"134"},{"groupId":"BG004","value":"37"},{"groupId":"BG005","value":"34"},{"groupId":"BG006","value":"344"}],"title":">=75 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"402"},{"groupId":"BG003","value":"403"},{"groupId":"BG004","value":"115"},{"groupId":"BG005","value":"115"},{"groupId":"BG006","value":"1054"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"243"},{"groupId":"BG003","value":"255"},{"groupId":"BG004","value":"88"},{"groupId":"BG005","value":"90"},{"groupId":"BG006","value":"694"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"23"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"127"},{"groupId":"BG003","value":"120"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"272"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"4"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"58"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}],"title":"Multiracial"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Included all participants who received at least 1 dose of study treatment (talazoparib or enzalutamide) in Part 1, and all participants who were randomized to double-blind study treatment in Part 2 regardless of whether or not treatment was administered."}